Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure(ATALANTE-1) | terminated | Phase 3 | 219 | OSE ImmunotherapeuticsINDUSTRY | 10 | Feb 2, 2024 | clinicaltrials |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma(BREC) | terminated | Phase 3 | 382 | Spanish Lung Cancer GroupOTHER | 1 |
| Jan 30, 2024 |
| clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01459497 | Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer | completed | Phase 3 | 103 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT01763645 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 3 | 353 | BiocadINDUSTRY | 4 | Jan 11, 2024 | clinicaltrials |
| NCT05318443 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 512 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03256981 | Stereotactic Body Radiotherapy for the Treatment of OPD(HALT) | unknown | Phase 2 / Phase 3 | 113 | Institute of Cancer Research, United KingdomOTHER | 5 | Dec 26, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | completed | Phase 3 | 492 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT04632758 | Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 3 | 292 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer(CanStem43L) | terminated | Phase 3 | 4 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | completed | Phase 3 | 452 | PfizerINDUSTRY | 7 | Nov 14, 2023 | clinicaltrials |
| NCT05673590 | Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 612 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06110663 | A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy | unknown | Phase 3 | 314 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | Nov 1, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT02864251 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy(CheckMate722) | completed | Phase 3 | 367 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT06041776 | Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations | recruiting | Phase 3 | 570 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06043973 | Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance | recruiting | Phase 3 | 98 | Qianfoshan HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06031597 | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | unknown | Phase 3 | 105 | Zhejiang Cancer HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06020352 | The Efficacy and Safety of KN046 Combined With Axitinib | unknown | Phase 2 / Phase 3 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | terminated | Phase 3 | 1 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05990127 | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 642 | AkesoINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05791097 | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.(AdvanTIG-306) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04466917 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 3 | 0 | AmgenINDUSTRY | 0 | Jul 3, 2023 | clinicaltrials |
| NCT03728556 | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer | completed | Phase 3 | 381 | CStone PharmaceuticalsINDUSTRY | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02766335 | Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | completed | Phase 2 / Phase 3 | 116 | SWOG Cancer Research NetworkNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02448992 | Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 90 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05001724 | KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent | terminated | Phase 2 / Phase 3 | 16 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT01257139 | Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments(ESOGIA) | completed | Phase 3 | 490 | Rennes University HospitalOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03991403 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | unknown | Phase 3 | 228 | Samsung Medical CenterOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT00385606 | Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC | completed | Phase 2 / Phase 3 | 400 | National Cancer Institute, NaplesOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT01763671 | Paclitaxel-bevacizumab in Advanced Lung Cancer(Ultimate) | completed | Phase 3 | 166 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT01850303 | Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer(MODEL) | completed | Phase 3 | 632 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT02041533 | An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) | completed | Phase 3 | 541 | Bristol-Myers SquibbINDUSTRY | 26 | Mar 2, 2023 | clinicaltrials |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients(eNERGY) | completed | Phase 3 | 217 | Rennes University HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03150875 | A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC | completed | Phase 3 | 290 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 2, 2024source: clinicaltrials